Compounded Semaglutide vs Wegovy

Compounded semaglutide vs Wegovy at a glance

Both products are built around semaglutide, a GLP-1 receptor agonist. The comparison stops there. Wegovy is a specific FDA-approved drug with a label that sets its indications, strengths, dosing schedule, storage rules, and warnings. Compounded semaglutide is whatever a particular pharmacy prepared for a particular prescription, and no FDA label describes it.

The table below lists the differences that change a purchase decision. Everything in the Wegovy column comes from the current label and Novo Nordisk's own pharmacy page. Everything in the compounded column comes from FDA's compounding pages, because there is no single compounded product to describe.

Is compounded semaglutide the same as Wegovy?

No. FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness, or quality before they are marketed. Wegovy went through that review; a compounded vial did not. Calling compounded semaglutide a generic Wegovy is wrong on both counts, because there is no approved generic semaglutide and a compounded product is not a generic of anything.

FDA also reports specific problems with unapproved GLP-1 products. Some compounders use semaglutide sodium or semaglutide acetate, which FDA says are different active ingredients from the base semaglutide in the approved drugs, with no safety data for those forms. FDA had received 990 adverse-event reports involving compounded semaglutide as of May 31, 2026, and describes dosing errors by patients and clinicians, products shipped warm, and doses that exceed the approved label.

None of that proves a given compounded vial is unsafe. It means the quality checks that stand behind Wegovy are absent, and the buyer has to ask the pharmacy and prescriber for them instead.

Who makes Wegovy and who compounds semaglutide

Novo Nordisk manufactures Wegovy and is the only source of the approved product. Compounded semaglutide comes from two kinds of facilities. A 503A pharmacy is a state-licensed pharmacy that compounds for individual prescriptions and is overseen day to day by its state board of pharmacy. A 503B outsourcing facility registers with FDA, follows current good manufacturing practice, and can compound larger batches without patient-specific prescriptions.

The legal basis for compounding semaglutide changed in 2025. FDA confirmed the semaglutide shortage resolved on February 21, 2025, and its enforcement discretion for compounders ended on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. FDA's April 2026 clarification says a 503A pharmacy may not regularly, or in inordinate amounts, compound a drug that is essentially a copy of a commercially available approved drug, and a 503B facility may not use bulk semaglutide because it is on neither the bulks list nor the shortage list. A telehealth program selling compounded semaglutide in 2026 should be able to explain which pharmacy fills it and why the prescription is not a routine copy.

How each one is dosed and stored

The Wegovy label starts the injection at 0.25 mg once weekly for four weeks and escalates every four weeks toward a usual maintenance dose of 2.4 mg once weekly, with a 7.2 mg Wegovy HD pen also listed. Single-dose pens and syringes stay in the refrigerator at 36°F to 46°F and, if needed, can be kept at up to 86°F for up to 28 days before the cap is removed. The FlexTouch pen holds four 2.4 mg doses and lasts 56 days after first use. Each pen delivers a fixed dose, so no measuring is involved.

Compounded semaglutide most often arrives as a multi-dose vial. The concentration depends on the pharmacy, the prescriber sets the dose, and the patient draws it up with a syringe. FDA lists dosing errors as a recurring source of adverse-event reports and advises discarding a multi-dose vial 28 days after first use and using a new sterile needle for every dose. Telehealth Ledger does not publish syringe-unit or concentration conversions; the pharmacy label and the prescriber's instructions are the only valid source for a compounded dose.

Do not use the Wegovy label to dose a compounded product, and do not switch between the two without the prescriber and pharmacy confirming the product, concentration, and schedule.

Where you buy Wegovy and where compounded semaglutide is sold

Wegovy is a prescription drug you can fill at a retail pharmacy, through insurance, or through NovoCare Pharmacy, Novo Nordisk's self-pay home-delivery channel. NovoCare's page says all doses require a prescription, offers free home delivery through its dispensing pharmacy, CoAssist Pharmacy, and lists telehealth prescribers and pharmacy pickup as options. A telehealth company can prescribe Wegovy, but it is still the same Novo Nordisk product filled by a licensed pharmacy.

Compounded semaglutide is sold almost entirely through telehealth programs. The program supplies the clinician visit, sends the prescription to a partner compounding pharmacy, and ships the vial. Because there is no manufacturer, the program's checkout page is the only price list. FDA's consumer advice is to obtain a prescription from a licensed doctor and fill it at a state-licensed pharmacy, and to treat sales without a prescription or clinician screening as a warning sign.

What Wegovy costs through Novo Nordisk and how compounded semaglutide is priced

Novo Nordisk publishes Wegovy self-pay prices on its NovoCare Pharmacy page. Patients new to the program pay $199 per month for the 0.25 mg and 0.5 mg pens for two monthly fills through December 31, 2026, then $349 per month for 0.25 mg through 2.4 mg pens and $399 per month for the 7.2 mg Wegovy HD pen, with a month defined as one box of four pens. The Wegovy pill costs $149 per month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg for a bottle of 30 tablets. People with commercial insurance may pay as little as $25 per month for up to three months, subject to a $100 monthly savings cap, and government beneficiaries are excluded. Eligible Medicare Part D beneficiaries pay a $50 copay through the Medicare GLP-1 Bridge, which covers all Wegovy formulations through December 31, 2027.

Compounded semaglutide has no list price. Each telehealth program sets a monthly or prepaid price that may or may not include the clinician visit, the medication, syringes, and shipping. The catalog module below shows current published telehealth prices for compounded semaglutide and Wegovy programs side by side, with the price basis and the date each was verified.

What to ask a telehealth provider before choosing

A short list of questions separates a transparent program from a vague one. The answers should be specific and written down before payment.

• Is this FDA-approved Wegovy from Novo Nordisk, or a compounded semaglutide product? Which pharmacy fills it, and in which state is it licensed?
• If compounded, is the ingredient base semaglutide or a salt form, what is the concentration, and what are the written measuring instructions?
• What does the monthly price include: clinician visits, medication, supplies, shipping, and follow-up?
• Is the first month an introductory price, and what is the continuing price after it ends?
• How is the product shipped and kept cold, and what happens if it arrives warm?
• What is the cancellation rule, and is any prepaid amount refundable if a clinician declines to prescribe?